News
BDX
233.76
+0.26%
0.61
ClearBridge Appreciation ESG Strategy Q1 2024 Portfolio Manager Commentary
Soft landing rally that took hold in November 2023 continued in 2024's first quarter. Every sector, except for real estate, posted positive absolute returns. The S&P 500's 10.56% quarterly advance was the 11th best start to a year since 1950. ClearBridge is watching sustainability-related opportunities presented by artificial intelligence.
Seeking Alpha · 1d ago
Buy on the Dip: These 3 Stocks Just Hit 52-Week Lows
47 NYSE and 157 Nasdaq stocks are hitting 52-week lows. The S&P 500 hit an all-time high on March 28. Three stocks to buy on the dip are Becton Dickinson, Chuy’s Holdings and Chipotle. The Tex-Mex restaurant chain is down nearly 12% over the past year.
Barchart · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 3d ago
BUZZ-Medical device makers fall after J&J's medtech unit misses sales estimates
Shares of medical device makers fall between 1% and 3% after Johnson & Johnson's JNJ.N medical devices unit reports Q1 sales of $7.82 bln. Analysts point to weakness in JNJ's vision care products and surgical devices. Stryker, Zimmer Biomet and Medtronic among those down.
Reuters · 3d ago
Weekly Report: what happened at BDX last week (0408-0412)?
Weekly Report · 4d ago
Are Becton, Dickinson and Company's (NYSE:BDX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Becton Dickinson's (NYSE:BDX) 5.1% return on equity is a useful tool to assess a company's ability to generate profits. The company's ROE is based on the ratio of its earnings to its shareholders' equity. BectonDick has a net income growth rate of 14% over the last five years. The stock has declined 4.5% since the company's last announcement. The firm's ROe is not as good as the industry average.
Simply Wall St · 5d ago
Steris: Moving On, Losing Its Teeth
Steris announced the sale of its dental segment for $787 million. The divestment will have a limited impact on the overall business, but it makes strategic sense. Steris remains a solid organic growth performer, but a more attractive entry point is needed before getting involved. The company is selling the dental segment, a non-core business acquired with the purchase of Cantel.
Seeking Alpha · 5d ago
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
NASDAQ · 04/12 15:04
3 Highest-Rated Dividend Kings To Buy and Hold Forever
NASDAQ · 04/11 13:45
ClearBridge Appreciation Strategy Q1 2024 Portfolio Manager Commentary
Soft landing rally that took hold in November 2023 continued in 2024’s first quarter. Every sector except real estate posted positive absolute returns. Paths to outperformance have — finally — broadened beyond mega cap tech. Near-term risks to the economy have seemingly abated.
Seeking Alpha · 04/10 05:50
BD Named a Best Employer for Excellence in Employee Well-Being
BD receives the Business Group on Health "Best Employers: Excellence in Health & Well-being Award" for its commitment to advancing employee well-being. BD is one of the largest global medical technology companies in the world. The company also garnered honors for "Excellence in Global Health and Well- Being"
PR Newswire · 04/09 14:15
GSH Corporation Announces Director Retirement
TipRanks · 04/09 09:48
YieldBoost Becton, Dickinson To 6.8% Using Options
NASDAQ · 04/08 15:36
BD's (BDX) Latest Product to Offer Wider Access to Researchers
NASDAQ · 04/08 14:27
Weekly Report: what happened at BDX last week (0401-0405)?
Weekly Report · 04/08 09:09
ClearBridge Dividend Strategy Q1 2024 Portfolio Manager Commentary
ClearBridge Dividend Strategy Q1 2024 Portfolio Manager Commentary. The market's rise continues to be led by a small handful of mega cap technology names. Information technology (IT) is now 2.25x the size of any other sector in the S&P 500 Index.
Seeking Alpha · 04/06 10:45
AngioDynamics upgraded at Oppenheimer on pipeline progress
AngioDynamics upgraded at Oppenheimer on pipeline progress to Outperform from Perform. FDA approved AlphaVac F1885 medical device for pulmonary embolism. The medical device maker's shares closed 5% higher on Thursday after the upgrade. Oppensheimer issued a $12 per share target on the stock.
Seeking Alpha · 04/05 13:19
BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters
NASDAQ · 04/05 11:09
Becton, Dickinson Announced Global Commercial Release Of New Cell Sorters To Enable More Researchers In Broader Range Of Fields, Including Cell Biology, Cancer Research And Immunology In Traditional Flow Cytometry Experiments
The new BD FACSDiscover S8 Cell Sorters feature BD CellView Image Technology and BD SpectralFX Technology. The new instruments bring breakthrough innovations in real-time imaging and spectral flow cytometry to the market. The three- and four-laser additions to the S8 family complement the five-year-old instrument.
Benzinga · 04/05 10:49
More
Webull provides a variety of real-time BDX stock news. You can receive the latest news about Becton Dickinson & Co through multiple platforms. This information may help you make smarter investment decisions.
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.